Treatment of unresectable hepatocellular carcinoma with 131I‐labeled CD147‐specific antibody metuximab (Licartin) combined with transcatheter arterial chemoembolization showed promising safety and efficacy (NCT00829465). This evidence concerns the gene BSG and hepatocellular carcinoma.